Although the efficacy of chimaeric antigen receptor (CAR) T cell therapy has been demonstrated in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), it has not been investigated in primary refractory DLBCL. In this phase I clinical trial, the authors report on the safety and efficacy of relmacabtagene autoleucel, a CD19-specific CAR T cell product, and demonstrate using single-cell RNA sequencing that cholesterol efflux from macrophages may impair CAR T cell responses in this context.
- Zi-Xun Yan
- Yan Dong
- Wei-Li Zhao
